Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 16,135 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

NCT01653964
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular breast imaging
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Nov 7, 2026, 1:08 PM EST
Not listed Phase 2 Interventional

Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers

NCT00366132
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
Extracorporeal Shockwaves
Device
Lead sponsor
Tissue Regeneration Technologies
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Washington D.C., District of Columbia • The Bronx, New York • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Nov 7, 2026, 1:08 PM EST
Active, not recruiting Not applicable Interventional

Lupus Education Alliance Program

NCT05243875
View directory record Official record
Conditions
Systemic Lupus Erythematosus, COVID-19
Interventions
LEAP Education + Navigation, LEAP Education
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 2 Interventional Results available

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

NCT03221257
View directory record Official record
Conditions
Scleroderma, Systemic, Interstitial Lung Disease
Interventions
Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional

Chemotherapy Induced Peripheral Neuropathy (CIPN)

NCT03272919
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Arm 1: Investigational INF, Arm 2: standardized muscle stretching and strength
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 7, 2026, 1:08 PM EST
Not listed Phase 2 Interventional

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

NCT00280930
View directory record Official record
Conditions
Post-Menopausal, Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Nov 7, 2026, 1:08 PM EST
Enrolling by invitation Phase 3 Interventional

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265
View directory record Official record
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

NCT02236000
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, T-DM1
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
15
States / cities
Weston, Florida • Decatur, Illinois • Effingham, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional Results available

Calcium Absorption in Patients With Rothmund-Thomson Syndrome

NCT01304407
View directory record Official record
Conditions
Rothmund-Thomson Syndrome
Interventions
Calcium stable isotope
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional

An Intimacy Intervention for Couples Completing Breast or Prostate Cancer

NCT04221607
View directory record Official record
Conditions
Sexual Dysfunction, Breast Cancer, Prostate Cancer
Interventions
Sensate Focus exercise
Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot

NCT03913936
View directory record Official record
Conditions
Breast Cancer
Interventions
YES portal
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 2 Interventional Results available

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Bevacizumab, Everolimus
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 7, 2026, 1:08 PM EST
Terminated Phase 3 Interventional Results available

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab/Vibostolimab, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older · Female only
Enrollment
1,363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Honolulu, Hawaii • Decatur, Illinois • New Orleans, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 7, 2026, 1:08 PM EST
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD1163, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional Results available

Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients

NCT00676130
View directory record Official record
Conditions
Cellulitis
Interventions
trimethoprim-sulfamethoxazole, Cephalexin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Months and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 2 Interventional Results available

Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

NCT01396837
View directory record Official record
Conditions
Neuropathic Diabetic Ulcer - Foot
Interventions
RedDress Wound Care System (RD1)
Device
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Miami, Florida • North Miami Beach, Florida • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

NCT02698657
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ASP5094, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples

NCT02051101
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Biopsy sample from Port Wine Stain Birthmark
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Day and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Nov 7, 2026, 1:08 PM EST
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 7, 2026, 1:08 PM EST
Terminated No phase listed Observational

Vulvar Mucosal Specialty Clinic Chart Review

NCT02881229
View directory record Official record
Conditions
Vulvar Disease, Lichen Sclerosus, Lichen Planus, Vulvodynia
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Nov 7, 2026, 1:08 PM EST
Completed Not applicable Interventional

IMpact of PRehabilitation in Oncology Via Exercise - Breast Cancer

NCT03498157
View directory record Official record
Conditions
Breast Cancer, Prehabilitation, Physical Activity, Surgery
Interventions
Exercise, Prehabilitation Education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Nov 7, 2026, 1:08 PM EST
Completed Phase 1 Interventional

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01231919
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Aggressive NK-cell Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Noncutaneous Extranodal Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Nov 7, 2026, 1:08 PM EST
Completed No phase listed Observational

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

NCT00658281
View directory record Official record
Conditions
Breast Cancer
Interventions
CBCT Scan, OBI KV Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Nov 7, 2026, 1:08 PM EST